1 Min Read
COPENHAGEN (Reuters) - Denmark's Novo Nordisk said on Wednesday it had received a subpoena in the United States regarding potential criminal offences relating to marketing and promotion practices for a number of its products.
The world's biggest maker of insulin said in a statement that the office of the United States attorney for the District of Massachusetts had asked for documents relating to Novo Nordisk's diabetes products Novolog, Levemir and Victoza.
Novo said it would cooperate with the attorney in the investigation, and that the group was at this point unable to determine or predict the outcome of the matter, or assess the consequences.
It was not possible to predict how long the investigation would take, Novo Nordisk said in the statement.